French medical device company Edap TMS asks the FDA for pre-market approval of its Ablatherm treatment for prostate cancer.
The Lyon, France-based medical device company said the high-intensity focused ultrasound device is designed to treat low-risk, localized prostate cancer. The PMA submission is backed by data from Edap's Enlight study, according to a press release.
"We have clearly seen a paradigm shift in prostate cancer, as patients are diagnosed earlier than ever before. Low-risk patients need a middle ground between radical treatment, which is often overly-aggressive, and the anxiety of 'watchful waiting.' Ablatherm-HIFU is well-positioned to address this unmet medical need by providing a unique non-invasive and fully robotic treatment option," CEO Marc Oczachowski said in prepared remarks .
French medical device company Edap TMS asks the FDA for pre-market approval of its Ablatherm treatment for prostate cancer. EDAP (NSDQ:EDAP) said it filed for pre-market approval of its Ablatherm-HIFU prostate cancer treatment from the FDA.